Philip E. Stauffer

Model-driven experimental approach reveals the complex regulatory distribution of p53 by the circadian factor Period 2

John J. Tyson, Carla V. Finkielstein, Jae Kyoung Kim, 2016, Proceedings of the National Academy of Sciences.

Ion channel dysregulation and ferroptosis susceptibility in a heterogeneous DTP state

Corey E. Hayford, L. A. Harris, V. Quaranta, 2022 .

Archetype tasks link intratumoral heterogeneity to plasticity and cancer hallmarks in small cell lung cancer.

Gabor T. Marth, Alissa M. Weaver, G. Marth, 2022, Cell systems.

An Integrative Gene Expression and Mathematical Flux Balance Analysis Identifies Targetable Redox Vulnerabilities in Melanoma Cells

Joshua E. Lewis, Corey E. Hayford, Keisha N. Hardeman, 2020, Cancer Research.

A heterogeneous drug tolerant persister state in BRAF-mutant melanoma is characterized by ion channel dysregulation and susceptibility to ferroptosis

Kaitlyn E. Johnson, Corey E. Hayford, L. A. Harris, 2022, bioRxiv.

Chronotherapy: Intuitive, Sound, Founded…But Not Broadly Applied

C. Finkielstein, D. Capelluto, Julia M Selfridge, 2016, Drugs.

CaMKIIα phosphorylation of Shank3 modulates ABI1-Shank3 interaction.

R. Colbran, Philip E. Stauffer, Keeley L. Spiess, 2020, Biochemical and biophysical research communications.

Purinergic calcium signaling drives drug tolerance through ERK reactivation in BRAF-mutant melanoma

Philip E. Stauffer, Darren R. Tyson, Jordon Brinkley, 2022 .

Purinergic Ca2+ Signaling as a Novel Mechanism of Drug Tolerance in BRAF-Mutant Melanoma

Philip E. Stauffer, Darren R. Tyson, Jordon Brinkley, 2023, bioRxiv.